Nonapprovable letter to Allergan

Share this article:
The FDA has issued a nonapprovable letter to Allergan for tazarotene capsules (oral tazarotene) for the treatment of psoriasis.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions